X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
GB0139 (olitigaltin) is an investigational small molecule inhibitor of galectin-3 that is administered as a once-daily inhalation via a generic dry powder inhaler. GB0139 is designed to specifically target galectin-3, a main regulator of the fibrosis cascade.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
GB0139 is an investigational inhaled small molecule inhibitor of galectin-3 that is administered as a once-daily inhalation via a generic dry powder inhaler. GB0139 is designed to specifically target galectin-3, a main regulator of the fibrosis cascade.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 23, 2023
Details:
GB0139 is an inhaled small molecule inhibitor of galectin-3 that is administered as a once-daily inhalation via a generic dry powder inhaler. GB0139 is designed to specifically target galectin-3, a main regulator of the fibrosis cascade.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Patients treated with GB0139 had a significantly greater rate of decline in oxygen requirement versus standard of care alone and showed other signs of reduced organ damage.
Lead Product(s): Olitigaltin
Therapeutic Area: Infections and Infectious Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
Details:
Patients with COVID-19 were able to inhale GB0139 and achieve consistent exposure of GB0139 at levels previously associated with systemic biomarker responses in IPF patients (including YKL-40 and PAI-1).
Lead Product(s): Olitigaltin
Therapeutic Area: Infections and Infectious Diseases Product Name: GB0139
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
The webinar will feature a presentation by Key Opinion Leader, who will discuss the current treatment landscape and unmet medical need in treating patients with IPF, as well as the clinical meaning of the exciting biomarker data on GB0139.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2021
Details:
The DSMB informed the company imbalance in the serious adverse experiences across the study groups. Galecto expects to continue recruiting patients who are not taking nintedanib or pirfenidone at screening and who would be randomized to receive GB0139 3 mg or placebo.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
Galecto's initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 to treat fibrosis. Its lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 for the treatment of severe fibrotic lung diseases.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 07, 2020
Details:
Galecto intends to use the funds to prepare for a potential conditional approval of GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) in the European Union and to further expand and advance its clinical development pipeline.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Soleus Capital
Deal Size: $64.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 25, 2020
Details:
Galecto has received Orphan Drug Designation (ODD) from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for GB0139 in the treatment of Idiopathic Pulmonary Fibrosis (IPF).
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: GB0139
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
The results showed that GB0139 is highly effective in the bleomycin model, including pharmacodynamic evidence with reduction of galectin-3.
Lead Product(s): Olitigaltin
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
